Marker Therapeutics

(NASDAQ) MRKR

Current Price$1.46

Market Cap$24.01M

Since IPO (2002)-100%

5 Year-94%

1 Year+30%

1 Month+4%

Marker Therapeutics Financials at a Glance

Market Cap

$24.01M

Revenue (TTM)

$3.55M

Net Income (TTM)

$12.16M

EPS (TTM)

$-0.91

P/E Ratio

-1.58

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$1.46

Volume

Open

$1.46

Price

$1.46

Volume

Open

$1.46

Previous Close

$1.46

Daily Range

$1.46 - $1.46

52-Week Range

$0.81 - $4.07

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$1.46

Volume

Open

$1.46

Previous Close

$1.46

Daily Range

$1.46 - $1.46

52-Week Range

$0.81 - $4.07

MRKR News

Here's Why Marker Therapeutics Fell as Much as 11.5% Today

Maxx ChatskoApr 17, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Marker Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Juan F. Vera, MD

Website

www.markertherapeutics.com

Headquarters

Houston, TX 77027, US

MRKR Financials

Key Financial Metrics (TTM)

Gross Margin

-1%

Operating Margin

-4%

Net Income Margin

-3%

Return on Equity

-69%

Return on Capital

-0%

Return on Assets

-0%

Earnings Yield

-63.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$24.01M

Shares Outstanding

16.67M

Volume

Avg. Volume

134.74K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$12.44M

EBITDA

$12.44M

Operating Cash Flow

$12.01T

Capital Expenditure

$0.00

Free Cash Flow

$12.01T

Cash & ST Invst.

$16.07T

Total Debt

$0.00

Marker Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$1.10M

-51.0%

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$24.01M

N/A

Market Cap/Employee

$4.80M

N/A

Employees

N/A

Net Income

$1.70M

+55.6%

EBITDA

$1.88M

+51.2%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$16.07T

+83720615.0%

Accounts Receivable

$1.37M

-41.7%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-0.00%

N/A

Return on Invested Capital

-0.00%

N/A

Free Cash Flow

$12.01T

-255448040.1%

Operating Cash Flow

$12.01T

-255448040.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SNSESensei Biotherapeutics, Inc.

SNSESensei Biotherapeutics, Inc.$23.40-1.52%

COCPCocrystal Pharma, Inc.

COCPCocrystal Pharma, Inc.$1.44+3.60%

PHIOPhio Pharmaceuticals Corp.

PHIOPhio Pharmaceuticals Corp.$1.07-6.14%

CLRBCellectar Biosciences, Inc.

CLRBCellectar Biosciences, Inc.$3.10-6.06%

BOLTBolt Biotherapeutics, Inc.

BOLTBolt Biotherapeutics, Inc.$4.67+1.74%

IMNNImunon, Inc.

IMNNImunon, Inc.$2.72-0.37%

EVGNEvogene Ltd.

EVGNEvogene Ltd.$0.75-3.75%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

RXTRackspace Technology

RXTRackspace Technology$5.49+0.56%

NVDANvidia

NVDANvidia$215.20+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$15.62+0.08%

IRENIren

IRENIren$61.20+0.08%

NOKNokia

NOKNokia$12.82+0.04%

POETPoet Technologies

POETPoet Technologies$10.95+0.14%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.28+0.07%

Questions About MRKR

What is the current price of Marker Therapeutics?

Marker Therapeutics is trading at $1.46 per share.

What is the 52-week range for Marker Therapeutics?

Over the past 52 weeks, Marker Therapeutics has traded between $0.81 and $4.07.

How much debt does Marker Therapeutics have?

As of the most recent reporting period, Marker Therapeutics reported total debt of N/A.

How much cash does Marker Therapeutics have on hand?

Marker Therapeutics reported $17.04M in cash and cash equivalents in its most recent financial results.

What is Marker Therapeutics’s dividend yield?

Marker Therapeutics does not currently have a dividend yield.

Marker Therapeutics

Marker Therapeutics Financials at a Glance

MRKR News

Here's Why Marker Therapeutics Fell as Much as 11.5% Today

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Marker Therapeutics

MRKR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Marker Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MRKR

What is the current price of Marker Therapeutics?

What is the 52-week range for Marker Therapeutics?

How much debt does Marker Therapeutics have?

How much cash does Marker Therapeutics have on hand?

What is Marker Therapeutics’s dividend yield?

Premium Investing Services